Drugs / CG400549
CG400549
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01848470 | May 2010 → Mar 2011 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01593761 | Jun → Sep 2012 | skin infection | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01085578 Comparator | Oct → Dec 2009 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG400549 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01593761 ↗ |
| Known as | CG-400459 | ChEMBL registry synonym — accepted as the source's own label CHEMBL488937 ↗ |
| Known as | Nilofabicin | ChEMBL registry synonym — accepted as the source's own label CHEMBL488937 ↗ |
| Modality | Small molecule | — CHEMBL488937 ↗ |
| Route | Oral | “a single oral dose of 80 mg CG400549 or placebo on Day 1” NCT01085578 ↗ |